Advertisement

Non-small cell lung cancer with pathological complete response: predictive factors and surgical outcomes

  • Hidenao Kayawake
  • Norihito OkumuraEmail author
  • Keiji Yamanashi
  • Ayuko Takahashi
  • Satoshi Itasaka
  • Hiroshige Yoshioka
  • Takashi Nakashima
  • Tomoaki Matsuoka
Original Article
  • 24 Downloads

Abstract

Objectives

When induction therapy followed by surgery for locally advanced non-small cell lung cancer results in pathological complete response, the prognosis is excellent; however, relapses can occur. We analyzed the predictive factors for achieving pathological complete response and reviewed the clinicopathological features and surgical outcomes of locally advanced non-small cell lung cancer with pathological complete response.

Methods

Between March 2005 and January 2015, 145 resections after induction therapy for locally advanced non-small cell lung cancer were performed; 38 cases achieved pathological complete response. Predictive factors for achieving pathological complete response were analyzed, and the clinicopathological features and surgical outcomes of 38 cases with pathological complete response were retrospectively reviewed.

Results

Of 145 patients, 98 underwent induction chemoradiation and 47, induction chemotherapy. Squamous cell carcinoma occurred most frequently (n = 64), followed by adenocarcinoma (n = 53). Only squamous cell carcinoma was positively associated with achieving pathological complete response (p = 0.009). Of 38 patients with pathological complete response, 33 were men and the mean age was 67.0 ± 6.3 years; the clinical stages were IIA (n = 3), IIB (n = 2), IIIA (n = 26), and IIIB (n = 3). One patient died within 30 days post-surgery (2.6%). Eight recurrences occurred during the follow-up period; brain metastasis occurred most frequently. The 5-year overall and recurrence-free survival rates were 79.5% and 72.6%, respectively.

Conclusions

Squamous cell carcinoma was identified as a positive predictive factor for achieving pathological complete response. Among patients undergoing lung cancer surgery after induction therapy with pathological complete response, brain metastasis occurred most frequently.

Keywords

Pathological complete response Induction therapy Lung cancer Surgical outcome Squamous cell carcinoma 

Notes

Acknowledgements

The authors thank Reiko Moriwake for his painstaking assistance with the data management.

Funding

No funding was provided.

Compliance with ethical standards

Conflict of interest

None declared.

Supplementary material

11748_2019_1076_MOESM1_ESM.tif (1.3 mb)
Supplemental Figure 1 (A) The overall survival of patients with squamous cell carcinoma who underwent surgical resection after induction therapy was compared between patients receiving and not receiving radiation therapy. There was no significant difference in overall survival. (B) Similarly, there was no significant difference in recurrence-free survival between patients receiving and not receiving radiation therapy (TIF 1342 KB)

References

  1. 1.
    Albain KS, Swann RS, Rusch VW, Turrisi AT III, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–86.CrossRefGoogle Scholar
  2. 2.
    Venuta F, Anile M, Diso D, Ibrahim M, De Giacomo T, Rolla M, et al. Operative complications and early mortality after induction therapy for lung cancer. Eur J Cardiothorac Surg. 2007;31:714–8.CrossRefGoogle Scholar
  3. 3.
    Koshy M, Fedewa SA, Malik R, Ferguson MK, Vigneswaran MT, Feldman L, et al. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non–small-cell lung cancer. J Thorac Oncol. 2013;8:915–22.CrossRefGoogle Scholar
  4. 4.
    Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet. 2015;386:1049–56.CrossRefGoogle Scholar
  5. 5.
    Marulli G, Verderi E, Zuin A, Schiavon M, Battistella L, Perissinotto E, et al. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection. Interact Cardiovasc Thorac Surg. 2014;19:256–62.CrossRefGoogle Scholar
  6. 6.
    Yokomise H, Gotoh M, Okamoto T, Yamamoto Y, Ishikawa S, Nakashima T, et al. Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007;133:1179–85.CrossRefGoogle Scholar
  7. 7.
    Isobe K, Hata Y, Sakaguchi S, Sato F, Takahashi S, Sato K, et al. Pathological response and prognosis of stage III non-small cell lung cancer patients treated with induction chemoradiation. Asia Pac J Clin Oncol. 2012;8:260–6.CrossRefGoogle Scholar
  8. 8.
    Chen AM, Jahan TM, Jablons DM, Garcia J, Larson DA. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer; clinical implications for the subsequent management of the brain. Cancer. 2007;109:1668–75.CrossRefGoogle Scholar
  9. 9.
    Lococo F, Cesario A, Margaritora S, Dall’Armi V, Mattei F, Romano R, et al. Long-term results in patients with pathological complete response after induction radiochemotherapy followed by surgery for locally advanced non-small-cell lung cancer. Eur J Cardiothorac Surg. 2013;43:e71–81.CrossRefGoogle Scholar
  10. 10.
    Momon HJ, Yeap BY, Ja¨nne PA, Reblando J, Shrager S, Jaklitsch MT, et al. High risk of brain metastases in surgically staged IIIA non–small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol. 2005;23:1530–7.CrossRefGoogle Scholar
  11. 11.
    Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC lung cancer staging project: proposals for the revision of the tnm stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.CrossRefGoogle Scholar
  12. 12.
    Kayawake H, Okumura N, Yamanashi K, Otsuki Y, Takahashi A, Itasaka S, et al. Surgical outcomes and complications of pneumonectomy after induction therapy for non-small cell lung cancer. Gen Thorac Cardiovasc Surg. 2018;66:658–63.CrossRefGoogle Scholar
  13. 13.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefGoogle Scholar
  14. 14.
    Kim AW, Liptay MJ, Bonomi P, Warren WH, Basu S, Farlow EC, et al. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg. 2011;92:233–43.CrossRefGoogle Scholar
  15. 15.
    Speicher PJ, Englum BR, Ganapathi AM, Onaitis MW, D’Amico TA, Berry MF. Outcomes after treatment of 17 378 patients with locally advanced (T3N0-2) non-small-cell lung cancer. Eur J Cardiothorac Surg. 2015;47:636–41.CrossRefGoogle Scholar
  16. 16.
    Katakami N, Tada H, Mitsudomi T, Kudoh S, Senba H, Matsui K, et al. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer. 2012;118:6126–35.CrossRefGoogle Scholar
  17. 17.
    Friedel G, Budach W, Dippon J, Spengler W, Echmann SM, Pfannenberg C, et al. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol. 2010;28:942–8.CrossRefGoogle Scholar
  18. 18.
    Barnett S, Rusch V, Zheng J, Park BJ, Rizk NP, Plourde G, et al. Contemporary results of surgical resection of non-small cell lung cancer after induction therapy; a review of 549 consecutive cases. J Thorac Oncol. 2011;6:1530–6.CrossRefGoogle Scholar
  19. 19.
    Mizuno T, Arimura T, Kuroda H, Sakakura N, Yatabe Y, Sakao Y. Histological type predicts mediastinal metastasis and surgical outcome in resected cN1 non-small cell lung cancer. Gen Thorac Cardiovasc Surg. 2017;65:519–26.CrossRefGoogle Scholar
  20. 20.
    Watanabe S, Asamura H, Suzuki K, Tsuchiya R. Problems in diagnosis and surgical management of clinical N1 non-small cell lung cancer. Ann Thorac Surg. 2005;79:1682–5.CrossRefGoogle Scholar
  21. 21.
    Nakao M, Yoshida J, Ishii G, Kawase A, Maeda R, Aokage K, et al. Prognostic impact of node involvement pattern in pN1 non-small cell lung cancer patients. J Thorac Oncol. 2010;5:1576–82.CrossRefGoogle Scholar
  22. 22.
    Chen F, Okubo K, Sonobe M, Shibuya K, Matsuo Y, Kim YH, et al. Hyperfractionated irradiation with 3 cycles of induction chemotherapy in stage IIIA-N2 lung cancer. World J Surg. 2012;36:2858–64.CrossRefGoogle Scholar
  23. 23.
    Lee J, Kim HK, Park BJ, Cho JH, Choi YS, Zo JI, et al. Recurrence dynamics after trimodality therapy (neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer. Lung Cancer. 2018;115:89–96.CrossRefGoogle Scholar
  24. 24.
    Kim HK, Choi YS, Kim K, Shim YM, Park K, Ahn YC, et al. Outcomes of mediastinoscopy and surgery with or without neoadjuvant therapy in patients with non-small cell lung cancer who are N2 negative on positron emission tomography and computed tomography. J Thorac Oncol. 2011;6:336–42.CrossRefGoogle Scholar
  25. 25.
    Uramoto H, Okumura M, Endo S, Tanaka F, Yokomise H, Masuda M. The 30-day mortality and hospital mortality after chest surgery described in the annual reports published by the Japanese Association for Thoracic and Cardiovascular Surgery. Gen Thorac Cardiovasc Surg. 2015;63:279–283.CrossRefGoogle Scholar
  26. 26.
    Toyooka S, Kiura K, Shien K, Katsui K, Hotta K, Kanazawa S, et al. Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg. 2012;15:954–60.CrossRefGoogle Scholar
  27. 27.
    Sato H, Toyooka S, Soh J, Hotta K, Katsui K, Shien K, et al. Advantage of induction chemoradiotherapy for lung cancer in securing cancer-free bronchial margin. Ann Thorac Surg. 2017;104:971–8.CrossRefGoogle Scholar

Copyright information

© The Japanese Association for Thoracic Surgery 2019

Authors and Affiliations

  1. 1.Department of Thoracic SurgeryKurashiki Central HospitalKurashiki-CityJapan
  2. 2.Department of Thoracic SurgeryKyoto UniversityKyotoJapan
  3. 3.Department of Radiation TherapyKurashiki Central HospitalOkayamaJapan
  4. 4.Department of Respiratory MedicineKurashiki Central HospitalOkayamaJapan

Personalised recommendations